Xiying Guo
Overview
Explore the profile of Xiying Guo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou X, Wang H, Yan B, Nie X, Chen Q, Yang X, et al.
Cardiovasc Drugs Ther
. 2024 Dec;
PMID: 39641901
Objective: Cardiovascular diseases (CVDs) are major public health problems that threaten the lives and health of individuals. The article has reviewed recent progresses about ferroptosis and ferroptosis-related intervention approaches for...
2.
Zhao B, Zhang Z, Guo X, Liu X, Lei M, Guo S, et al.
Int Urol Nephrol
. 2024 Nov;
57(3):875-884.
PMID: 39520637
Renal ischemia-reperfusion injury (RIRI) is a serious kidney condition that causes significant damage due to lack of blood flow. This injury leads to oxidative stress and inflammation, which can cause...
3.
Zhou Q, Guo X, Chen T, Liu Y, Ji H, Sun Y, et al.
Biomed Pharmacother
. 2024 Sep;
179:117397.
PMID: 39232386
Celastrol, the primary constituent of Tripterygium wilfordii, has demonstrated neuroprotective properties in rats with dementia by reducing inflammation. A high-fat diet and streptozotocin injection were utilized to establish a diabetic...
4.
Wang P, Lan Q, Huang Q, Zhang R, Zhang S, Yang L, et al.
Biology (Basel)
. 2024 Aug;
13(8).
PMID: 39194535
Diabetic nephropathy (DN) is one of the common complications of diabetes and the main cause of end-stage renal disease (ESRD) in clinical practice. Schisandrin A (Sch A) has multiple pharmacological...
5.
Yuan Y, Zhang Y, Lei M, Guo X, Yang X, Ouyang C, et al.
Int J Endocrinol
. 2024 Feb;
2024:9294113.
PMID: 38379936
Purpose: Type 2 diabetes mellitus is considered as one of the risk factors for cognitive impairment. DPP4 inhibitors are effective drugs for the treatment of type 2 diabetes mellitus. However,...
6.
Zhou Z, Ou-Yang C, Chen Q, Ren Z, Guo X, Lei M, et al.
Front Immunol
. 2023 Dec;
14:1287130.
PMID: 38152400
Evidence from clinical research and animal studies indicates that inflammation is an important factor in the occurrence and development of cardiovascular disease (CVD). Emerging evidence shows that nucleic acids serve...
7.
Guo X, Lei M, Ma G, Ouyang C, Yang X, Liu C, et al.
Mol Neurobiol
. 2023 Nov;
61(5):2514-2529.
PMID: 37910285
Clinical and epidemiological research shows that people with diabetes mellitus frequently experience diabetic cognitive impairment. Schisandrin A (SchA), one of the lignans found in the dried fruit of Schisandra chinensis,...
8.
Lei M, Guo X, Yao Y, Shu T, Ren Z, Yang X, et al.
Exp Gerontol
. 2023 Oct;
182:112307.
PMID: 37804920
Cognitive impairment frequently coexists with diabetes. Trelagliptin is a once-weekly taking selective dipeptidyl peptidase-4 (DPP-4) inhibitor and a long-term effective hypoglycemic medicine; nonetheless, its effects for the treatment of diabetes-related...
9.
Guo X, Lei M, Zhao J, Wu M, Ren Z, Yang X, et al.
Front Pharmacol
. 2023 Sep;
14:1146960.
PMID: 37701028
One of the typical symptoms of diabetes mellitus patients was memory impairment, which was followed by gradual cognitive deterioration and for which there is no efficient treatment. The anti-diabetic incretin...
10.
Zhou C, Yang Y, Ling Hu , Meng X, Guo X, Lei M, et al.
Toxicol In Vitro
. 2023 Aug;
93:105662.
PMID: 37597758
This study aimed to investigate the effect of miRNAs involving oxidative stress response in doxorubicin (DOX)-induced cardiotoxicity based on the data from Gene Expression Omnibus (GEO) database and experimental results...